Articles producció científica> Medicina i Cirurgia

Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment

  • Identification data

    Identifier: imarina:9294660
    Authors:
    Masana, LPlana, NAndreychuk, NIbarretxe, D
    Abstract:
    Statins have contributed to the prevention of numerous atherosclerotic cardiovascular (CV) events and cardiovascular deaths in the past three decades. The benefit of statins is mainly mediated by the lowering of LDLc. According to scientific evidence, the current international guidelines recommend very low LDLc goals in patients at high/very high cardiovascular risk because they are associated with fewer CV events and improvements in atherosclerotic plaques. However, these goals often cannot be obtained with statins alone. Recent RCTs have demonstrated that these CV benefits can also be obtained with nonstatin LDLc-lowering drugs such as PCSK9 inhibitors (alirocumab and evolocumab), ezetimibe and bempedoic acid, while evidence with inclisiran is upcoming. Icosapent ethyl, a lipid metabolism modifier, has also shown an effect on event reduction. Physicians should take advantage of the currently available lipid-lowering therapies, choosing the drug or combination of drugs that is most appropriate for each patient according to his or her CV risk and baseline LDLc concentration. Strategies implementing combination therapies from early stages or even from the outset may increase the number of patients attaining LDLc goals, thereby preventing new CV episodes and improving existing atherosclerotic lesions.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
  • Others:

    Author, as appears in the article.: Masana, L; Plana, N; Andreychuk, N; Ibarretxe, D
    Department: Medicina i Cirurgia
    URV's Author/s: Andreychuk Pasichna, Natalia / Ibarretxe Gerediaga, Daiana / Masana Marín, Luis / Plana Gil, Núria
    Keywords: Statin Lipid-lowering therapy Inclisiran Icosapent ethyl High-risk patients Ezetimibe Evolocumab Combination therapy Cardiovascular prevention Bempedoic acid Atherosclerosis treatment Alirocumab statin society safety progression outcomes lipid-lowering therapy ldl-cholesterol inclisiran icosapent ethyl ezetimibe evolocumab efficacy coronary combination therapy cardiovascular events bempedoic acid atherosclerosis treatment alirocumab
    Abstract: Statins have contributed to the prevention of numerous atherosclerotic cardiovascular (CV) events and cardiovascular deaths in the past three decades. The benefit of statins is mainly mediated by the lowering of LDLc. According to scientific evidence, the current international guidelines recommend very low LDLc goals in patients at high/very high cardiovascular risk because they are associated with fewer CV events and improvements in atherosclerotic plaques. However, these goals often cannot be obtained with statins alone. Recent RCTs have demonstrated that these CV benefits can also be obtained with nonstatin LDLc-lowering drugs such as PCSK9 inhibitors (alirocumab and evolocumab), ezetimibe and bempedoic acid, while evidence with inclisiran is upcoming. Icosapent ethyl, a lipid metabolism modifier, has also shown an effect on event reduction. Physicians should take advantage of the currently available lipid-lowering therapies, choosing the drug or combination of drugs that is most appropriate for each patient according to his or her CV risk and baseline LDLc concentration. Strategies implementing combination therapies from early stages or even from the outset may increase the number of patients attaining LDLc goals, thereby preventing new CV episodes and improving existing atherosclerotic lesions.Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
    Thematic Areas: Química Pharmacology & pharmacy Pharmacology Odontología Medicina ii Medicina i Interdisciplinar Farmacia Engenharias iv Engenharias ii Enfermagem Educação física Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciência de alimentos Biotecnología Biodiversidade Astronomia / física
    licence for use: https://creativecommons.org/licenses/by/3.0/es/
    Author's mail: daiana.ibarretxe@urv.cat luis.masana@urv.cat natalia.andreychuk@urv.cat
    Author identifier: 0000-0002-0789-4954
    Record's date: 2024-08-03
    Papper version: info:eu-repo/semantics/publishedVersion
    Link to the original source: https://www.sciencedirect.com/science/article/pii/S1043661823000944?via%3Dihub
    Licence document URL: https://repositori.urv.cat/ca/proteccio-de-dades/
    Papper original source: Pharmacological Research. 190 106738-106738
    APA: Masana, L; Plana, N; Andreychuk, N; Ibarretxe, D (2023). Lipid lowering combination therapy: From prevention to atherosclerosis plaque treatment. Pharmacological Research, 190(), 106738-106738. DOI: 10.1016/j.phrs.2023.106738
    Article's DOI: 10.1016/j.phrs.2023.106738
    Entity: Universitat Rovira i Virgili
    Journal publication year: 2023
    Publication Type: Journal Publications
  • Keywords:

    Pharmacology,Pharmacology & Pharmacy
    Statin
    Lipid-lowering therapy
    Inclisiran
    Icosapent ethyl
    High-risk patients
    Ezetimibe
    Evolocumab
    Combination therapy
    Cardiovascular prevention
    Bempedoic acid
    Atherosclerosis treatment
    Alirocumab
    statin
    society
    safety
    progression
    outcomes
    lipid-lowering therapy
    ldl-cholesterol
    inclisiran
    icosapent ethyl
    ezetimibe
    evolocumab
    efficacy
    coronary
    combination therapy
    cardiovascular events
    bempedoic acid
    atherosclerosis treatment
    alirocumab
    Química
    Pharmacology & pharmacy
    Pharmacology
    Odontología
    Medicina ii
    Medicina i
    Interdisciplinar
    Farmacia
    Engenharias iv
    Engenharias ii
    Enfermagem
    Educação física
    Ciências biológicas iii
    Ciências biológicas ii
    Ciências biológicas i
    Ciência de alimentos
    Biotecnología
    Biodiversidade
    Astronomia / física
  • Documents:

  • Cerca a google

    Search to google scholar